Eiger Biopharmaceuticals (Celladon)

^{Acquired, Nasdaq: EIGR}

Developing a first-in-class gene therapy for patients with systolic heart failure.

Industry: Health Care

First Day Return: +2.3%

EIGR

Developing a first-in-class gene therapy for patients with systolic heart failure.

IPO News for Eiger Biopharmaceuticals (Celladon)

US IPO Recap: Ultragenyx doubles and Dicerna triples in home-run week for biotech IPOs 02/03/14
Celladon prices upsized IPO at $8 01/29/14
Celladon revises terms, drops IPO price to $8 01/28/14

IPO Data
IPO Date	01/29/2014
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$44
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.celladon.net
Headquarters	San Diego, CA, United States
Founded	2000
Employees at IPO	15

IPO News for Eiger Biopharmaceuticals (Celladon)

US IPO Recap: Ultragenyx doubles and Dicerna triples in home-run week for biotech IPOs 02/03/14
Celladon prices upsized IPO at $8 01/29/14
Celladon revises terms, drops IPO price to $8 01/28/14

Eiger Biopharmaceuticals (Celladon) (EIGR) Performance